Connect with us

Insight

The missing layer in the women’s health conversation

Published

on

By Jenny Duan, co-founder of Clair Health

In the lead up to International Women’s Day 2026, women’s health leaders, experts and insiders explore the critical challenges shaping the future of women’s health

“When was your last period?”

For many women, that’s the first, and often only, hormone-related question asked during a doctor’s visit.

A complex system that influences everything from sleep quality to pain sensitivity is reduced to a singular data point: a date.

This simplification reflects a medical system shaped by decades of a lack of research in women’s health, where cyclical information was treated as a confounding factor, rather than a foundational pillar of health.

In fact, until 1993, the National Institutes of Health did not require women to be included in clinical trials.

Because of this, diagnostic frameworks were built to recognise the steady baselines of male physiology, leaving hormone-driven symptoms disregarded, and ultimately misunderstood.

I witnessed this first-hand in high school, when I volunteered at Rose Haven, a nonprofit for women and children experiencing homelessness and domestic violence.

Many of the women I worked with described debilitating symptoms, yet were met with dismissal from healthcare providers.

Without quantitative data to validate it, their symptoms were minimised.

This was the first time I understood that what cannot be measured is not taken seriously, even when someone is sitting in front of you telling you that they feel something is wrong.

The women at Rose Haven weren’t the only ones who experienced this dismissal.

Nearly 70 per cent of women with polycystic ovary syndrome (PCOS) remain undiagnosed. The average time to diagnose endometriosis is seven years.

Even cardiovascular disease, the leading cause of death among women, is more frequently misdiagnosed because symptom checklists were originally developed using male data.

These are the patterns that emerge when hormones are ignored, and while awareness has increased, many of the insight solutions available today remain outdated.

When it comes to getting hormones measured, the process lacks efficiency, accessibility, and even accuracy.

Blood tests provide a single snapshot in time, both expensive and invasive, and ultimately disconnected from daily experience.

                      Jenny Duan

Ovulation strips require precise timing and daily interpretation, confirming a surge only as it’s happening, and basal body temperature tracking tells you ovulation has already occurred.

Although more recently developed, calendar-based apps still rely on population averages, assuming 28-day cycle regularity when nearly one in three women experience irregular cycles.

Each method is either reactive or fragmented, again attempting to simplify dynamic and individualised patterns.

The opportunity in femtech today is to build systems that embrace and interpret that complexity rather than reduce it to one hormone level from three days prior.

With continuous data collection and smarter analytical models, we can begin to see hormonal patterns as they unfold in real time.

Hormone health is the missing layer in the women’s health conversation, and for decades, women have navigated their health without the tools to help them understand it.

The idea for Clair Health came from that realisation.

At Stanford, I met my co-founder, Abhinav Agarwal, and we bonded over a shared thought that healthcare innovation, especially wearable health technology, had not been built with women in mind.

Devices had been collecting heart rate, temperature, HRV, and sleep data for years, but no one had built the algorithms to translate those signals into hormonal insight.

Clair was created to change that, continuously monitoring hormones to give women a personalized understanding of their hormone health, and how the state of their hormones influences everyday well-being.

Clair is grounded in the belief that women should not have to guess when it comes to their health.

By translating continuous physiological signals into individualised patterns over time, the goal is to make hormone health more interpretable and ultimately let women understand their overall health by taking information into their own hands.

When women have access to longitudinal insight, symptoms become contextualised within patterns, and care can move from reactive to preventative.

Femtech is entering a period of acceleration as technology advances and research gaps begin to close.

The next chapter of this industry must build the infrastructure that reflects women’s unique biology.

Clair won’t force healthcare providers to ask better questions, but it will equip women with the data to back up their symptoms when they walk into the room.

When this information becomes accessible through innovations in this space, women begin to have a long-overdue and deeper understanding of their health.

Insight

New pregnancy treatment shows promise for at-risk twins

Published

on

A high-powered ultrasound treatment could help identical twins affected by a rare and serious condition during early pregnancy, an initial study suggests.

Twin-to-twin transfusion syndrome, or TTTS, causes uneven blood flow between identical twins who share a placenta.

The imbalance can leave one baby dangerously small and the other too large, putting both babies’ survival at risk.

 

Brioney Garrett’s daughters were in danger before doctors used the world-first treatment to seal the blood vessels causing the problem without an operation.

Nancy and Margo were born healthy and, now aged four, are due to start school.

Researchers from Queen Charlotte’s and Chelsea Hospital tested the non-invasive procedure in 10 women from the UK and elsewhere in Europe after scans detected TTTS during early pregnancy.

Five women needed further treatment, while 12 of the 20 babies survived following the procedure.

The researchers described having a treatment that did not require a needle or telescope to be inserted into the mother’s abdomen as “extremely exciting”.

However, they said larger studies involving more pregnant women were needed before the procedure could be offered more widely.

Garrett described her daughters as “my miracle twins”.

She said: “We were in a very dire situation and I don’t forget that.

“It stays with me always how things could have been. Every day I still count my blessings.”

TTTS affects between 10 and 15 per cent of identical twins who share a placenta, representing around 300 to 400 pregnancies in the UK each year.

The uneven blood flow causes excess fluid to build up around the larger recipient baby, while leaving dangerously little fluid around the smaller donor baby.

Treatment usually involves inserting a needle into the womb to drain some of the fluid or using a laser to seal the connecting blood vessels.

Garrett’s procedure took about 20 minutes. She lay flat while a specially designed machine directed high-powered ultrasound waves at small blood vessels in her placenta.

She said: “It was very quick and pretty painless.”

Christoph Lees, head of fetal medicine at Imperial College Healthcare NHS Trust and professor of obstetrics at Imperial College London, described the research as “very promising”.

He said: “If this could work in a fully-fledged study, it could give hope to a lot of women who otherwise might have to have quite invasive treatment.”

Ultrasound is commonly used during medical scans to produce images of the body, but this procedure uses much more focused waves.

Heat generated by the waves can seal blood vessels about 2mm in diameter and located around 5cm to 6cm beneath the skin.

The procedure blocked blood flow in 90 per cent of the vessels treated during the study, with no unwanted side-effects reported.

Twins Trust, which supported the study, said the approach could make a significant difference for families affected by TTTS.

Helen Peck, head of healthcare engagement and research, said: “Any procedure that is non-invasive and can potentially identify TTTS earlier and improve outcomes for our families with this life-threatening condition could be a turning point.”

Scans carried out weeks after Garrett’s procedure showed that blood flow between the babies had been rebalanced, although other problems developed during the pregnancy.

Garrett said Margo, who had too little fluid around her, “was in a much better position” and that “the strain on Nancy’s heart had eased”.

Nancy and Margo were born at nearly 34 weeks, weighing 3lb 7oz and 3lb 3oz respectively.

Garrett said: “They were both healthy, and Margo wasn’t as small as we worried she was going to be.”

The twins are due to start primary school in September.

Garrett said: “They’re funny, smart, energetic little girls that just fit right in with their age group.”

Continue Reading

Insight

Breast cancer rising rapidly in Asian American women, study finds

Published

on

Breast cancer rates have risen rapidly among Asian American women over the past two decades, with some of the steepest increases among women under 50, new research has revealed.

Rates rose by more than three per cent a year in nearly every Asian American ethnic group studied, much faster than in any other US ethnic group.

The increase was particularly marked among women under 50 and in cases involving advanced-stage disease or certain aggressive subtypes of the cancer.

The study found even larger increases among Chinese and Vietnamese women.

Breast cancer rates among Native Hawaiian women were already among the highest recorded among US women, but rose by about one per cent a year, less than the increases seen in Asian American groups.

The researchers said increased screening was unlikely to explain the trend because screening would be expected to identify more cancers at an earlier stage.

Instead, cancers that had already spread increased at the fastest rate.

Triple-negative breast cancer, considered the most aggressive subtype, rose by more than six per cent a year among Chinese American women between 2017 and 2022.

Scarlett Lin Gomez, senior author and professor of epidemiology and biostatistics at the University of California, San Francisco, said: “These patterns are highly concerning from a disparities standpoint.

“They underscore why it is so important to move beyond treating Asian Americans, Native Hawaiians, and Pacific Islanders as a single population.”

Researchers analysed about 150,000 cases of invasive breast cancer diagnosed between 2000 and 2022 using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results Programme.

The analysis covered nine Asian American, Native Hawaiian and Pacific Islander populations across 14 states. Together, these states account for about two-thirds of the US population within these groups.

Except for Native Hawaiian women, Asian American women have historically had lower breast cancer rates than non-Hispanic white women.

However, the gap has narrowed rapidly. By 2022, incidence among Asian American women under 50 was comparable with that recorded among white women.

The reasons for the increase among women under 50 remain unclear.

Changes in reproductive patterns, diet and other lifestyle factors may play a part, but researchers said they did not fully explain the findings.

They said previously unidentified risk factors may also be contributing to the rises in some Asian American communities.

Researchers hope two UCSF-based studies, the CRANE breast cancer study and the ASPIRE cohort study, will provide insights into these factors.

Gomez said: “Understanding why breast cancer is increasing so rapidly in these communities is critical.

“At the same time, we need to ensure that women across all Asian American, Native Hawaiian, and Pacific Islander communities have access to culturally appropriate education, screening, and timely follow-up care.”

Continue Reading

Fertility

Softening ovaries could extend fertility as women age, study suggests

Published

on

Softening ageing ovaries could help women remain fertile for longer, early animal research suggests.

Fertility declines with age for several reasons, including poorer egg quality, fewer ovarian follicles and the gradual stiffening of ovarian tissue.

Existing fertility treatments, including hormone therapy and in vitro fertilisation, mainly address hormonal imbalances or help eggs mature or become fertilised.

Scientists are now examining whether changing the physical structure of the ovaries could provide another route for future fertility treatments.

Stuart A. Cook, of the Cardiovascular and Metabolic Disorders Programme at Duke-National University of Singapore Medical School, published an accompanying commentary on the research.

Researchers led by Shixuan Wang at Huazhong University of Science and Technology in Wuhan, China, collected healthy ovarian tissue from younger, middle-aged and older women.

They also examined samples from patients with polycystic ovary syndrome, known as PCOS, premature ovarian insufficiency, or POI, and endometriosis.

PCOS is a hormonal condition that can disrupt ovulation. POI occurs when the ovaries stop working normally before the age of 40, while endometriosis causes tissue similar to the womb lining to grow elsewhere in the body.

Tests of protein levels and gene activity found higher levels of the inflammatory protein interleukin-11, or IL-11, in ageing and diseased ovaries.

In laboratory experiments, the researchers exposed ovarian fibroblasts to IL-11. Fibroblasts are cells that produce connective tissue.

The protein caused the cells to produce excess collagen, a structural material that can build up during scarring and make tissue stiffer.

The researchers then genetically modified mice so they could not respond to IL-11. The animals developed less ovarian stiffening and maintained better ovarian function as they aged.

Similar results were seen in mouse models of PCOS and POI caused by chemotherapy.

In the final part of the experiment, older mice and rats were injected with a nanoparticle treatment containing small interfering RNA, or siRNA, designed to switch off IL-11.

The treatment made the animals’ ovaries less stiff and improved fertility.

Pregnancy rates among older mice rose from 25 per cent to 50 per cent, while average litter sizes also increased.

More rats treated with the therapy became pregnant and produced larger litters.

The approach remains highly speculative and will require considerably more research before its safety or effectiveness in women can be established.

However, the researchers said blocking the inflammatory pathway could eventually form the basis of new fertility treatments.

They said: “We propose that anti-IL-11 therapy represents a promising translational strategy for delaying ovarian ageing.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.